SEC Form 4 · accession 0001193125-26-273013
Parabilis Medicines, Inc. · PBLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alan Sebulsky
Director
Period of report
Jun 12, 2026
Accepted (ET)
Jun 16, 2026 · 6:19 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001657677
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 12, 2026 | P | 8,435 | $27.6696 | A | 20,935 | I | By Apothecary Capital LLC |
| Common StockF3,F2 | Jun 15, 2026 | P | 5,000 | $25.9978 | A | 25,935 | I | By Apothecary Capital LLC |
| Common StockF4,F2 | Jun 15, 2026 | P | 4,065 | $27.0963 | A | 30,000 | I | By Apothecary Capital LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.16 to $28.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes 1, 3 and 4 to this Form 4.
- F2Represents shares held by Apothecary Capital LLC ("Apothecary Capital"). The Reporting Person is the managing member of Apothecary Capital and may be deemed to share voting, investment and dispositive power with respect to the securities held by Apothecary Capital. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- F3The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.61 to $26.25, inclusive.
- F4The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.00 to $27.20, inclusive.